Skip to main content

Day: December 22, 2022

Else Announces Closing of First Tranche of Institutional Investment for Gross Proceeds of US$4.25M

VANCOUVER, British Columbia, Dec. 22, 2022 (GLOBE NEWSWIRE) — ELSE NUTRITION HOLDINGS INC. (TSX: BABY) (OTCQX: BABYF) (FSE: 0YL) (the “Company”) is pleased to announce that it has closed the first tranche of the previously announced private placement pursuant to the convertible security funding agreement (the “Agreement”) with Lind Global Fund II LP, an entity managed by The Lind Partners, LLC, a New York-based institutional fund manager (together, “Lind”) for net proceeds of US$4,133,125 after deduction of the original issue discount and closing fee (the “First Tranche”). Pursuant to the First Tranche, the Company has issued: (i) a convertible security (the “Initial Convertible Security”) with a two-year term and a face value of US$5,100,000; and (ii) 8,247,129 common share purchase warrants (the “Warrants”) exercisable into common...

Continue reading

Mega Uranium Acquires Additional Securities of Green Shift Commodities

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, Dec. 22, 2022 (GLOBE NEWSWIRE) — Mega Uranium Ltd. (MGA: TSX) (“Mega” or the “Company”) announces that it has acquired ownership of an additional 3,333,333 common shares and 3,333,333 common share purchase warrants (the “Purchased Securities”) of Green Shift Commodities Ltd. (the “Issuer”), pursuant to a private placement of units completed by the Issuer on December 22, 2022 (“Closing”). The Purchased Securities were acquired by Mega at an aggregate cost of $500,000, or $0.15 per unit (with each unit comprised of one common share and one common share purchase warrant), and represent an increase of approximately 2.3% in the percentage of the Issuer’s outstanding common shares held by Mega, on an undiluted basis, and an increase...

Continue reading

Global Sciences and Pure BioPlastics Inc., Terminates the Letter of Intent for Acquisition

DENVER, CO, Dec. 22, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – Global Sciences, Inc. (OTC: CBDNF) (CSE: CBDN) (Frankfurt: GS3.F) (Munich: GS3.MU), “CBD Global” or the “Company”), announces that it has terminated the letter of intent with Pure Vision Technologies for the acquisition of 100% of Pure BioPlastics Inc., a renewable plastics company in Ft. Lupton Colorado (the “PBP”). Both companies worked tirelessly to accomplish the diligence that would lead to the execution of a Definitive Agreement, however, it has been mutually decided to cancel the letter of intent for this acquisition due to the inability to navigate the list of diligence required for this transaction to close.  Brad Wyatt, CEO of Global Sciences, shared, “I looked forward to working with Ed and the team at Pure Vision Technologies; their mission to reduce global...

Continue reading

Green Shift Commodities Closes Private Placement

TORONTO, Dec. 22, 2022 (GLOBE NEWSWIRE) — Green Shift Commodities Ltd. (TSXV: GCOM), (“Green Shift” or the “Company”) is pleased to announce that it has closed its previously announced non-brokered private placement financing of units (the “Units”) of the Company at a price of $0.15 per Unit (the “Issue Price”), for gross proceeds of $2,307,055.65 (the “Offering”). The Company issued an aggregate of 15,380,371 Units with each Unit consisting of one common share in the capital of the Company (each, a “Common Share”) and one Common Share purchase warrant (each, a “Warrant”). Each Warrant entitles the holder to purchase one Common Share at an exercise price of $0.25 until December 22, 2024. Trumbull Fisher, CEO and Director of Green Shift commented, “With the completion of this financing, we are entering 2023 in a stronger financial...

Continue reading

AAR increases size and extends maturity of revolving credit facility

Wood Dale, Illinois, Dec. 22, 2022 (GLOBE NEWSWIRE) — AAR CORP. (NYSE: AIR), a leading provider of aviation services to commercial and government operators, MROs, and OEMs, recently entered into a $620 million unsecured revolving credit facility. The credit facility is a $20 million increase from the prior facility and extends the maturity of the agreement from September 2024 to December 2027. “We are pleased to have both increased and extended our unsecured revolving credit facility, which recognizes the strength of our credit profile and provides us with significant liquidity and certainty,” said Dylan Wolin, Vice President, Strategic & Corporate Development and Treasurer of AAR CORP. “We would like to thank our lenders for their continued support.” Additional detail can be found in the Credit Agreement filed with AAR’s...

Continue reading

CytomX Therapeutics to Outline 2023 Company Priorities and Provide Pipeline Update on January 5, 2023

SOUTH SAN FRANCISCO, Calif., Dec. 22, 2022 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that it plans to outline its pipeline priorities for 2023 and provide a data update for the CX-2029 Phase 2 cohort expansion study, on Thursday, January 5, 2023, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT to discuss updates. Participants may access the live webcast of the conference call from the Events and Presentations page of CytomX’s website at https://ir.cytomx.com/events-and-presentations. Participants may register for the conference call here and are advised to do so at least 10 minutes prior to joining the call. An archived replay of...

Continue reading

VICTORY RESOURCES CORPORATION ANNOUNCES SHARE CONSOLIDATION AND NAME CHANGE TO VICTORY BATTERY METALS CORP.

Vancouver, Dec. 22, 2022 (GLOBE NEWSWIRE) — VANCOUVER, BC, CANADA (December 22, 2022) – Victory Resources Corporation (CSE: VR) (FWB: VR61) (OTC: VRCFF) (“Victory” or the “Company”) is pleased to announce that it intends to proceed with a name change to “Victory Battery Metals Corp.” (the “Name Change”) and consolidation of its common shares on the basis of three (3) pre-consolidation common shares for one (1) post-consolidation common share of the Company (the “Share Consolidation”). The Board of Directors approved the Name Change and Share Consolidation on December 16, 2022. The Company currently has 127,611,222 common shares issued and outstanding.  Accordingly, once the Share Consolidation is effective, the Company will have 42,537,074 common shares issued and outstanding, assuming there are no other changes in the issued capital...

Continue reading

R1 RCM to Present at the 41st Annual J.P. Morgan Health Care Conference

MURRAY, Utah, Dec. 22, 2022 (GLOBE NEWSWIRE) — R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced its management team will present at the 41st Annual J.P. Morgan Health Care Conference on Tuesday, January 10, 2023, at 7:30 am PT. A live audio webcast of the presentation will be available on the Investor Relations section of R1’s website at r1rcm.com. A replay of the webcast will be available for 30 days following the live webcast. About R1 RCM R1 is a leading provider of technology-driven solutions that transform the patient experience and financial performance of hospitals, health systems, and medical groups. R1’s proven and scalable operating models seamlessly complement a healthcare organization’s...

Continue reading

Applied Molecular Transport Announces Top-line Phase 2 Results from LOMBARD Monotherapy Trial of Oral AMT-101 in Patients with Moderate-to-Severe Ulcerative Colitis

– Similar clinical remission rates observed in patients receiving AMT-101 monotherapy compared to placebo at week 12 – AMT-101 was well-tolerated – Planned Phase 1b trial for the company’s second clinical asset, AMT-126, in UC patients – Exploring strategic partnership options to advance AMT-101 into Phase 3 in patients with chronic pouchitis – Strong cash position of $76M reported in Q3 2022 SOUTH SAN FRANCISCO, Calif., Dec. 22, 2022 (GLOBE NEWSWIRE) — Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT) today announced top-line Phase 2 results from the LOMBARD monotherapy trial for AMT-101 in biologic-naïve and experienced patients with moderate-to-severe ulcerative colitis (UC). AMT-101 is an investigational, once-daily, GI-selective, oral fusion of IL-10 and AMT’s proprietary carrier molecule. The clinical remission (CR) rate...

Continue reading

Petrus Resources Announces Monthly Activity Update

CALGARY, Alberta, Dec. 22, 2022 (GLOBE NEWSWIRE) — Petrus Resources Ltd. (“Petrus” or the “Company”) (TSX: PRQ) is pleased to announce the most recent version of the Company’s monthly activity update can be found on the Company’s website at https://www.petrusresources.com/monthlyupdates. ABOUT PETRUSPetrus is a public Canadian oil and gas company focused on property exploitation, strategic acquisitions and risk-managed exploration in Alberta. FOR FURTHER INFORMATION PLEASE CONTACT:Ken Gray President and Chief Executive Officer T: 403-930-0889 E: kgray@petrusresources.com

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.